相关实验视频

Updated: Jul 6, 2025

Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood

Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood

Published on: January 6, 2022

调节静脉血栓形成的内皮原生细胞的非编码RNA:有前途的疗法和创新

Li-Li Sun¹, Zhao Liu¹, Feng Ran¹

¹Department of Vascular Surgery, Nanjing Drum Tower Hospital, The Affiliate Hospital of Nanjing University Medical School, #321 Zhongshan Road, Nanjing, 210008, Jiangsu, China.

Stem cell research & therapy

|January 3, 2024

概括

非编码RNA可以改善内皮原生细胞功能,为静脉血栓栓塞 (VTE) 提供新的治疗点. 研究探索了这些分子如何调节DVT和肺栓塞中的EPC,帮助未来的治疗.

科学领域:

血管生物学血管生物学
分子医学是分子医学.
基因组学就是基因组学.

背景情况:

静脉血栓塞栓症 (VTE),包括深静脉血栓症 (DVT) 和肺栓塞,是全球主要的血管疾病,治疗疗效有限.
内皮原生细胞 (EPCs) 对于 DVT 解决至关重要,但它们的功能受到促血栓微环境的影响.
非编码RNAs (ncRNAs),包括长非编码RNAs和microRNAs,正在成为EPC功能的关键调节者和潜在的治疗点.

研究的目的:

在VTE的背景下,审查ncRNAs在调节EPC功能的作用.
探索ncRNAs影响DVT和肺栓塞中的EPCs的分子机制.
为VTE提供新的诊断,预防和治疗策略提供理论基础.

主要方法:

文献综述和现有实验和理论研究的综合.
分析EPC在静脉血栓形成和解决过程中的作用.
研究EPC上的长非编码RNA和microRNA的调控功能.

主要成果:

EPCs对于DVT再通道化至关重要,但在疾病微环境中,它们的有效性受到损害.
非编码RNA显著调节EPC的生物功能,影响VTE的发展.
ncRNAs显示出作为VTE干预的生物标志物和治疗点的前景.

结论:

了解EPCs的ncRNA调节对于推进VTE治疗至关重要.
非编码RNA代表了开发新型VTE疗法的有希望的途径.
本综述为未来对基于ncRNA的静脉血栓塞栓症干预措施的研究提供了基础.

关键词:

深静脉血栓形成的原因是深静脉血栓.内皮前代细胞是内皮前代细胞没有编码的RNAs.再生医学是一种再生医学.

更多相关视频

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

Decellularization and Recellularization Methodology for Human Saphenous Veins

Decellularization and Recellularization Methodology for Human Saphenous Veins

Published on: July 27, 2018

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...